Clinical outcome in chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation: the experience of the Bone Marrow Transplantation Unit of FUNFARME/BRAZIL using FISH

Investigation of the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in chronic myeloid leukemia patients is essential to predict prognosis and survival. In 20 patients treated at the Bone Marrow Transplantation Unit of São José do Rio Preto (São Paulo, Brazil), we used fl...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Genetics and molecular research 2008-01, Vol.7 (2), p.417-423
Hauptverfasser: Vendrame-Goloni, C B, Carvalho-Salles, A B, Ruiz, M A, Ricci Júnior, O, Varella-Garcia, M, Fett-Conte, A C
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 423
container_issue 2
container_start_page 417
container_title Genetics and molecular research
container_volume 7
creator Vendrame-Goloni, C B
Carvalho-Salles, A B
Ruiz, M A
Ricci Júnior, O
Varella-Garcia, M
Fett-Conte, A C
description Investigation of the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in chronic myeloid leukemia patients is essential to predict prognosis and survival. In 20 patients treated at the Bone Marrow Transplantation Unit of São José do Rio Preto (São Paulo, Brazil), we used fluorescence in situ hybridization (FISH) to investigate the frequency of cells with BCR/ABL rearrangement at diagnosis and at distinct intervals after allo-HSCT until complete cytogenetic remission (CCR). We investigated the disease-free survival, overall survival in 3 years and transplant-related mortality rates, too. Bone marrow samples were collected at 1, 2, 3, 4, 6, 12, and 24 months after transplantation and additional intervals as necessary. Success rate of the FISH analyses was 100%. CCR was achieved in 75% of the patients, within on average of 3.9 months; 45% patients showed CCR within 60 days after HSCT. After 3 years of the allo-HSCT, overall survival rate was 60%, disease-free survival was 50% and the transplant-related mortality rate was 40%. The study demonstrated that the BCR-ABL FISH assay is useful for follow-up of chronic myeloid leukemia patients after HSCT and that the clinical outcome parameters in our patient cohort were similar to those described for other bone marrow transplantation units.
doi_str_mv 10.4238/vol7-2gmr396
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71670267</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>21209663</sourcerecordid><originalsourceid>FETCH-LOGICAL-c315t-b02f860c9dc5d73f0161aa43b849a456a609d4da4c1bc7ca5ff213f82f05c2573</originalsourceid><addsrcrecordid>eNqFkU1v1DAQhiMEoqVw44x84kRaf8ROwm276tKVtkUq3QuXyOuMdw3-SG0H6G_jz5FtV4KeOM3Mq2deaeYtircEn1aUNWc_gq1LunWRteJZcUxELUouGvz8n_6oeJXSN4wprxr8sjgiDeekws1x8XtujTdKWhTGrIIDZDxSuxgmEbl7sMH0yML4HZyRSOoMEUlrwxY8TMQOnMxhCAbyNKUMDimwFuUofRqs9FlmE_xHlHeA4NcA0YBXgIJ-UM6DB3QlYww_0e3TFbT2Ju-5xfp6Mbu5ujg7v5l9Xa7QmIzfosXyy-Xr4oWWNsGbQz0p1ouL2_llufr8aTmfrUrFCM_lBlPdCKzaXvG-ZhoTQaSs2KapWllxIQVu-6qXlSIbVSvJtaaE6YZqzBXlNTsp3j_6DjHcjZBy50zanyk9hDF19fRnTMX_QUooboVgE_jhEVQxpBRBd0M0Tsb7juBun2q3T7U7pDrh7w6-48ZB_xc-xMj-ADbVogs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>21209663</pqid></control><display><type>article</type><title>Clinical outcome in chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation: the experience of the Bone Marrow Transplantation Unit of FUNFARME/BRAZIL using FISH</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Vendrame-Goloni, C B ; Carvalho-Salles, A B ; Ruiz, M A ; Ricci Júnior, O ; Varella-Garcia, M ; Fett-Conte, A C</creator><creatorcontrib>Vendrame-Goloni, C B ; Carvalho-Salles, A B ; Ruiz, M A ; Ricci Júnior, O ; Varella-Garcia, M ; Fett-Conte, A C</creatorcontrib><description>Investigation of the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in chronic myeloid leukemia patients is essential to predict prognosis and survival. In 20 patients treated at the Bone Marrow Transplantation Unit of São José do Rio Preto (São Paulo, Brazil), we used fluorescence in situ hybridization (FISH) to investigate the frequency of cells with BCR/ABL rearrangement at diagnosis and at distinct intervals after allo-HSCT until complete cytogenetic remission (CCR). We investigated the disease-free survival, overall survival in 3 years and transplant-related mortality rates, too. Bone marrow samples were collected at 1, 2, 3, 4, 6, 12, and 24 months after transplantation and additional intervals as necessary. Success rate of the FISH analyses was 100%. CCR was achieved in 75% of the patients, within on average of 3.9 months; 45% patients showed CCR within 60 days after HSCT. After 3 years of the allo-HSCT, overall survival rate was 60%, disease-free survival was 50% and the transplant-related mortality rate was 40%. The study demonstrated that the BCR-ABL FISH assay is useful for follow-up of chronic myeloid leukemia patients after HSCT and that the clinical outcome parameters in our patient cohort were similar to those described for other bone marrow transplantation units.</description><identifier>ISSN: 1676-5680</identifier><identifier>EISSN: 1676-5680</identifier><identifier>DOI: 10.4238/vol7-2gmr396</identifier><identifier>PMID: 18551408</identifier><language>eng</language><publisher>Brazil</publisher><subject>Adolescent ; Adult ; Bone Marrow Transplantation ; Brazil ; Disease-Free Survival ; Hematopoietic Stem Cell Transplantation - methods ; Hospital Departments ; Humans ; In Situ Hybridization, Fluorescence - methods ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - surgery ; Middle Aged ; Prognosis ; Survival Rate ; Transplantation, Homologous ; Treatment Outcome</subject><ispartof>Genetics and molecular research, 2008-01, Vol.7 (2), p.417-423</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18551408$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vendrame-Goloni, C B</creatorcontrib><creatorcontrib>Carvalho-Salles, A B</creatorcontrib><creatorcontrib>Ruiz, M A</creatorcontrib><creatorcontrib>Ricci Júnior, O</creatorcontrib><creatorcontrib>Varella-Garcia, M</creatorcontrib><creatorcontrib>Fett-Conte, A C</creatorcontrib><title>Clinical outcome in chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation: the experience of the Bone Marrow Transplantation Unit of FUNFARME/BRAZIL using FISH</title><title>Genetics and molecular research</title><addtitle>Genet Mol Res</addtitle><description>Investigation of the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in chronic myeloid leukemia patients is essential to predict prognosis and survival. In 20 patients treated at the Bone Marrow Transplantation Unit of São José do Rio Preto (São Paulo, Brazil), we used fluorescence in situ hybridization (FISH) to investigate the frequency of cells with BCR/ABL rearrangement at diagnosis and at distinct intervals after allo-HSCT until complete cytogenetic remission (CCR). We investigated the disease-free survival, overall survival in 3 years and transplant-related mortality rates, too. Bone marrow samples were collected at 1, 2, 3, 4, 6, 12, and 24 months after transplantation and additional intervals as necessary. Success rate of the FISH analyses was 100%. CCR was achieved in 75% of the patients, within on average of 3.9 months; 45% patients showed CCR within 60 days after HSCT. After 3 years of the allo-HSCT, overall survival rate was 60%, disease-free survival was 50% and the transplant-related mortality rate was 40%. The study demonstrated that the BCR-ABL FISH assay is useful for follow-up of chronic myeloid leukemia patients after HSCT and that the clinical outcome parameters in our patient cohort were similar to those described for other bone marrow transplantation units.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Bone Marrow Transplantation</subject><subject>Brazil</subject><subject>Disease-Free Survival</subject><subject>Hematopoietic Stem Cell Transplantation - methods</subject><subject>Hospital Departments</subject><subject>Humans</subject><subject>In Situ Hybridization, Fluorescence - methods</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - surgery</subject><subject>Middle Aged</subject><subject>Prognosis</subject><subject>Survival Rate</subject><subject>Transplantation, Homologous</subject><subject>Treatment Outcome</subject><issn>1676-5680</issn><issn>1676-5680</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU1v1DAQhiMEoqVw44x84kRaf8ROwm276tKVtkUq3QuXyOuMdw3-SG0H6G_jz5FtV4KeOM3Mq2deaeYtircEn1aUNWc_gq1LunWRteJZcUxELUouGvz8n_6oeJXSN4wprxr8sjgiDeekws1x8XtujTdKWhTGrIIDZDxSuxgmEbl7sMH0yML4HZyRSOoMEUlrwxY8TMQOnMxhCAbyNKUMDimwFuUofRqs9FlmE_xHlHeA4NcA0YBXgIJ-UM6DB3QlYww_0e3TFbT2Ju-5xfp6Mbu5ujg7v5l9Xa7QmIzfosXyy-Xr4oWWNsGbQz0p1ouL2_llufr8aTmfrUrFCM_lBlPdCKzaXvG-ZhoTQaSs2KapWllxIQVu-6qXlSIbVSvJtaaE6YZqzBXlNTsp3j_6DjHcjZBy50zanyk9hDF19fRnTMX_QUooboVgE_jhEVQxpBRBd0M0Tsb7juBun2q3T7U7pDrh7w6-48ZB_xc-xMj-ADbVogs</recordid><startdate>20080101</startdate><enddate>20080101</enddate><creator>Vendrame-Goloni, C B</creator><creator>Carvalho-Salles, A B</creator><creator>Ruiz, M A</creator><creator>Ricci Júnior, O</creator><creator>Varella-Garcia, M</creator><creator>Fett-Conte, A C</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20080101</creationdate><title>Clinical outcome in chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation: the experience of the Bone Marrow Transplantation Unit of FUNFARME/BRAZIL using FISH</title><author>Vendrame-Goloni, C B ; Carvalho-Salles, A B ; Ruiz, M A ; Ricci Júnior, O ; Varella-Garcia, M ; Fett-Conte, A C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c315t-b02f860c9dc5d73f0161aa43b849a456a609d4da4c1bc7ca5ff213f82f05c2573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Bone Marrow Transplantation</topic><topic>Brazil</topic><topic>Disease-Free Survival</topic><topic>Hematopoietic Stem Cell Transplantation - methods</topic><topic>Hospital Departments</topic><topic>Humans</topic><topic>In Situ Hybridization, Fluorescence - methods</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - surgery</topic><topic>Middle Aged</topic><topic>Prognosis</topic><topic>Survival Rate</topic><topic>Transplantation, Homologous</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vendrame-Goloni, C B</creatorcontrib><creatorcontrib>Carvalho-Salles, A B</creatorcontrib><creatorcontrib>Ruiz, M A</creatorcontrib><creatorcontrib>Ricci Júnior, O</creatorcontrib><creatorcontrib>Varella-Garcia, M</creatorcontrib><creatorcontrib>Fett-Conte, A C</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Genetics and molecular research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vendrame-Goloni, C B</au><au>Carvalho-Salles, A B</au><au>Ruiz, M A</au><au>Ricci Júnior, O</au><au>Varella-Garcia, M</au><au>Fett-Conte, A C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical outcome in chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation: the experience of the Bone Marrow Transplantation Unit of FUNFARME/BRAZIL using FISH</atitle><jtitle>Genetics and molecular research</jtitle><addtitle>Genet Mol Res</addtitle><date>2008-01-01</date><risdate>2008</risdate><volume>7</volume><issue>2</issue><spage>417</spage><epage>423</epage><pages>417-423</pages><issn>1676-5680</issn><eissn>1676-5680</eissn><abstract>Investigation of the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in chronic myeloid leukemia patients is essential to predict prognosis and survival. In 20 patients treated at the Bone Marrow Transplantation Unit of São José do Rio Preto (São Paulo, Brazil), we used fluorescence in situ hybridization (FISH) to investigate the frequency of cells with BCR/ABL rearrangement at diagnosis and at distinct intervals after allo-HSCT until complete cytogenetic remission (CCR). We investigated the disease-free survival, overall survival in 3 years and transplant-related mortality rates, too. Bone marrow samples were collected at 1, 2, 3, 4, 6, 12, and 24 months after transplantation and additional intervals as necessary. Success rate of the FISH analyses was 100%. CCR was achieved in 75% of the patients, within on average of 3.9 months; 45% patients showed CCR within 60 days after HSCT. After 3 years of the allo-HSCT, overall survival rate was 60%, disease-free survival was 50% and the transplant-related mortality rate was 40%. The study demonstrated that the BCR-ABL FISH assay is useful for follow-up of chronic myeloid leukemia patients after HSCT and that the clinical outcome parameters in our patient cohort were similar to those described for other bone marrow transplantation units.</abstract><cop>Brazil</cop><pmid>18551408</pmid><doi>10.4238/vol7-2gmr396</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1676-5680
ispartof Genetics and molecular research, 2008-01, Vol.7 (2), p.417-423
issn 1676-5680
1676-5680
language eng
recordid cdi_proquest_miscellaneous_71670267
source MEDLINE; EZB-FREE-00999 freely available EZB journals
subjects Adolescent
Adult
Bone Marrow Transplantation
Brazil
Disease-Free Survival
Hematopoietic Stem Cell Transplantation - methods
Hospital Departments
Humans
In Situ Hybridization, Fluorescence - methods
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - surgery
Middle Aged
Prognosis
Survival Rate
Transplantation, Homologous
Treatment Outcome
title Clinical outcome in chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation: the experience of the Bone Marrow Transplantation Unit of FUNFARME/BRAZIL using FISH
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T12%3A02%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20outcome%20in%20chronic%20myeloid%20leukemia%20after%20allogeneic%20hematopoietic%20stem%20cell%20transplantation:%20the%20experience%20of%20the%20Bone%20Marrow%20Transplantation%20Unit%20of%20FUNFARME/BRAZIL%20using%20FISH&rft.jtitle=Genetics%20and%20molecular%20research&rft.au=Vendrame-Goloni,%20C%20B&rft.date=2008-01-01&rft.volume=7&rft.issue=2&rft.spage=417&rft.epage=423&rft.pages=417-423&rft.issn=1676-5680&rft.eissn=1676-5680&rft_id=info:doi/10.4238/vol7-2gmr396&rft_dat=%3Cproquest_cross%3E21209663%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=21209663&rft_id=info:pmid/18551408&rfr_iscdi=true